FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Thomas, McNerney & Partners II L.P.   2. Issuer Name and Ticker or Trading Symbol CAS MEDICAL SYSTEMS INC [CASM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O JAMES THOMAS, 263 TRESSER BOULEVARD, 9TH FLOOR 3. Date of Earliest Transaction (Month/Day/Year) 04/18/2019 (Street) STAMFORD, CT 06901 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/18/2019   C   6,802,834 A $ 2.389 (1) 8,393,871 D   Common Stock 04/18/2019   C   24,125 A $ 2.389 (2) 30,063 I by TMP Associates II LP Common Stock 04/18/2019   C   71,075 A $ 2.389 (3) 79,100 I by TMP Nominee II, LLC Common Stock 04/18/2019   C   3,906,315 A $ 2.389 (4) 12,300,186 D   Common Stock 04/18/2019   C   13,881 A $ 2.389 (5) 43,944 I by TMP Associates II LP Common Stock 04/18/2019   C   40,772 A $ 2.389 (6) 119,872 I by TMP Nominee II, LLC Common Stock 04/18/2019   D   12,300,186 D $ 2.45 (7) 0 D   Common Stock 04/18/2019   D   43,944 D $ 2.45 (7) 0 I by TMP Associates II LP Common Stock 04/18/2019   D   119,872 D $ 2.45 (7) 0 I by TMP Nominee II, LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	04/18/2019		C			94,182	(1)	(1)	Common Stock	6,802,834	$ 0	0	D
Series A Convertible Preferred Stock	(2)	04/18/2019		C			334	(2)	(2)	Common Stock	24,125	$ 0	0	I	by TMP Associates II LP
Series A Convertible Preferred Stock	(3)	04/18/2019		C			984	(3)	(3)	Common Stock	71,075	$ 0	0	I	by TMP Nominee II, LLC
Series A Exchangeable Preferred Stock	(4)	04/18/2019		C			53,748	(4)	(4)	Common Stock	3,906,315	$ 0	0	D
Series A Exchangeable Preferred Stock	(5)	04/18/2019		C			191	(5)	(5)	Common Stock	13,881	$ 0	0	I	by TMP Associates II LP
Series A Exchangeable Preferred Stock	(6)	04/18/2019		C			561	(6)	(6)	Common Stock	40,772	$ 0	0	I	by TMP Nominee II, LLC

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Thomas, McNerney & Partners II L.P. C/O JAMES THOMAS 263 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901		X
Thomas, McNerney & Partners II, LLC C/O JAMES THOMAS 263 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901		X
TMP Associates II LP C/O JAMES THOMAS 263 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901		X
TMP Nominee II, LLC C/O JAMES THOMAS 263 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901		X

Signatures

Thomas, McNerney & Partners II, L.P. By: Thomas, McNerney & Partners II, LLC, its General Partner By: /s/James E. Thomas, Manager		04/22/2019
**Signature of Reporting Person		Date
Thomas, McNerney & Partners II, LLC, By: /s/James E. Thomas, Manager		04/22/2019
**Signature of Reporting Person		Date
TMP Associates II, L.P. By: Thomas, McNerney & Partners II, LLC, its General Partner By: /s/James E. Thomas, Manager		04/22/2019
**Signature of Reporting Person		Date
TMP Nominee II, LLC By: /s/James E. Thomas, Manager		04/22/2019
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reporting person converted 94,182 shares of Series A Convertible Preferred Stock on April 18, 2019, resulting in its acquisition of 6,802,834 shares of common stock. The Series A Convertible Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(2)	The reporting person converted 334 shares of Series A Convertible Preferred Stock on April 18, 2019, resulting in its acquisition of 24,125 shares of common stock. The Series A Convertible Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(3)	The reporting person converted 984 shares of Series A Convertible Preferred Stock on April 18, 2019, resulting in its acquisition of 71,075 shares of common stock. The Series A Convertible Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(4)	The reporting person converted 53,748 shares of Series A Exchangeable Preferred Stock on April 18, 2019, resulting in its acquisition of 3,906,315 shares of common stock. The Series A Exchangeable Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(5)	The reporting person converted 191 shares of Series A Exchangeable Preferred Stock on April 18, 2019, resulting in its acquisition of 13,881 shares of common stock. The Series A Exchangeable Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(6)	The reporting person converted 561 shares of Series A Exchangeable Preferred Stock on April 18, 2019, resulting in its acquisition of 40,772 shares of common stock. The Series A Exchangeable Preferred Stock was convertible into common stock at any time by converting the accreted value thereof into common stock at a conversion price of $2.389 per share, and had no expiration date.
(7)	Each issued and outstanding share of common stock was, as a result of the consummation of the merger contemplated by the Agreement and Merger by and among CAS Medical Systems, Inc., Edwards Lifesciences Holding, Inc. and Crown Merger Sub, Inc., dated as of February 11, 2019 (the "Merger Agreement"), canceled in exchange for the right to receive a per share amount equal to $2.45 in cash without interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.